Abstract:In this paper, we explore the utility of resting-state EEG measures as potential biomarkers for the detection and assessment of cognitive decline in mild cognitive impairment (MCI) and Alzheimer’s disease (AD). Neurophysiological biomarkers of AD derived from EEG and FDG-PET, once characterized and validated, would expand the set of existing diagnostic molecular biomarkers of AD pathology with associated biomarkers of disease progression and neural dysfunction. Since symptoms of AD often begin to appear later in life, successful identification of EEG-based biomarkers must account for age-related neurophysiological changes that occur even in healthy individuals. To this end, we collected EEG data from individuals with AD (n = 26), MCI (n = 53), and cognitively normal healthy controls stratified by age into three groups: 18–40 (n = 129), 40–60 (n = 62) and 60–90 (= 55) years old. For each participant, we computed power spectral density at each channel and spectral coherence between pairs of channels. Compared to age matched controls, in the AD group, we found increases in both spectral power and coherence at the slower frequencies (Delta, Theta). A smaller but significant increase in power of slow frequencies was observed for the MCI group, localized to temporal areas. These effects on slow frequency spectral power opposed that of normal aging observed by a decrease in the power of slow frequencies in our control groups. The AD group showed a significant decrease in the spectral power and coherence in the Alpha band consistent with the same effect in normal aging. However, the MCI group did not show any significant change in the Alpha band. Overall, Theta to Alpha ratio (TAR) provided the largest and most significant differences between the AD group and controls. However, differences in the MCI group remained small and localized. We proposed a novel method to quantify these small differences between Theta and Alpha bands’ power using empirically derived distributions of spectral power across the time domain as opposed to averaging power across time. We defined Power Distribution Distance Measure (PDDM) as a distance measure between probability distribution functions (pdf) of Theta and Alpha power. Compared to average TAR, using PDDF enhanced the statistical significance, the effect size, and the spatial distribution of significant effects in the MCI group. We designed classifiers for differentiating individual MCI and AD participants from age-matched controls. The classification performance measured by the area under ROC curve after cross-validation were AUC = 0.85 and AUC = 0.6, for AD and MCI classifiers, respectively. Posterior probability of AD, TAR, and the proposed PDDM measure were all significantly correlated with MMSE score and neuropsychological tests in the AD group.

Dynamics of the "Cognitive" Brain Wave P3b at Rest for Alzheimer Dementia Prediction in Mild Cognitive Impairment

Spatiotemporal EEG Dynamics of Prospective Memory in Ageing and Mild Cognitive Impairment

The Changes of Central Auditory Processing Function and Its Electroencephalogram in Patients with Mild Cognitive Impairment and Early Alzheimer’s Disease

Resting state EEG biomarkers of cognitive decline associated with Alzheimer’s disease and mild cognitive impairment

P300 Latency with Memory Performance: A Promising Biomarker for Preclinical Stages of Alzheimer's Disease

What a Single Electroencephalographic (EEG) Channel Can Tell us About Alzheimer's Disease Patients With Mild Cognitive Impairment

Exploring the neuromagnetic signatures of cognitive decline from mild cognitive impairment to Alzheimer's disease dementia

EEG and ERP biosignatures of mild cognitive impairment for longitudinal monitoring of early cognitive decline in Alzheimer's disease

Electrophysiological markers of rapid cognitive decline in mild cognitive impairment

Brain source localization of MMN and P300 ERPs in mild cognitive impairment and Alzheimer's disease: a high-density EEG approach

Resting State Eeg Multiscale Entropy Dynamics in Mild Cognitive Impairment and Early Alzheimer'S Disease

Resting EEG Discrimination of Early Stage Alzheimer’s Disease from Normal Aging Using Inter-Channel Coherence Network Graphs

PROGNOSIS OF CONVERSION TO MILD COGNITIVE IMPAIRMENT AND TIME TO STABLE CHANGES VIA MEMORY-RELATED ELECTROPHYSIOLOGICAL BRAIN SIGNATURES

Diagnostic Value of Event-Related Evoked Potentials N200 and P300 Subcomponents in Early Diagnosis of Alzheimer’s Disease and Mild Cognitive Impairment

P1‐325: Predicting Progression to Mild Cognitive Impairment in Cognitively Unimpaired Individuals Using Neuroimaging Biomarkers

Clinical study of P300 and electroencephalogram in elderly patients with mild cognitive impairment

MEASUREMENT OF BRAIN EVOKED POTENTIAL CHANGES AND THEIR PREDICTIVE VALUE OF MILD COGNITIVE IMPAIRMENT IN THE ELDERLY

Spectral and complexity analysis of scalp EEG characteristics for mild cognitive impairment and early Alzheimer's disease

IC‐P‐089: Can Three Months MRI Volumetric Parameters Help the Prediction of Progression from MCI to Alzheimer's Disease? Results from the Addneuromed Study

P3‐360: IMPAIRED BRAIN SPONTANEOUS ACTIVITY OF ALZHEIMER DISEASE REVEALED BY MULTICENTER RESTING FMRI (N=688)

Neural Biomarker Diagnosis and Prediction to Mild Cognitive Impairment and Alzheimer’s Disease Using EEG Technology